Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.

NCT01570790 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT01570790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01570790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.
Lead sponsor
Johns Hopkins University
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2003
Completion date
June 30, 2005
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, amd, choroidal neovascularization, cnv, combretastatin a4 phosphate